Therapy for MYD88 L265P DLBCL

Blood, vol. 145, pp. 998–1000

DOI: 10.1182/blood.2024027538 OpenAlex

Authors 2

Joost S.P. Vermaat Aachen

Leiden University Medical Center

Affiliation as printed

Leiden University Medical Center
Ruben A. L. de Groen Aachen

Leiden University Medical Center

Affiliation as printed

Leiden University Medical Center

Cited by 3 stored of 3

3 results

References 10

Oncogenically active MYD88 mutations in human lymphoma
2010 Nature article Medicine Lymphoma Diagnosis and Treatment Open access

1,546

citations
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL
2021 Cancer Cell article Medicine Lymphoma Diagnosis and Treatment Open access

316

citations
Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial
2023 Cancer Cell article Medicine Lymphoma Diagnosis and Treatment Open access

130

citations
Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma
2022 British Journal of Haematology article Medicine Chronic Lymphocytic Leukemia Research Open access

99

citations
High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma
2018 Blood article Medicine Lymphoma Diagnosis and Treatment Open access

94

citations
MYD88 in the driver’s seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications
2019 Haematologica article Medicine Lymphoma Diagnosis and Treatment Open access

86

citations
MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis
2019 Haematologica article Medicine Lymphoma Diagnosis and Treatment Open access

84

citations
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
2024 New England Journal of Medicine article Medicine Lymphoma Diagnosis and Treatment Open access

74

citations
Genetic Stability of Driver Alterations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type and Their Relapses: A Rationale for the Use of Molecular-Based Methods for More Effective Disease Monitoring
2022 Cancers article Medicine Cutaneous lymphoproliferative disorders research Open access

16

citations
Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation
2024 Blood article Medicine Lymphoma Diagnosis and Treatment

5

citations

10 results